Does Capital BlueCross cover Zepbound?

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• BMI documentation meeting threshold (≥ 30 kg/m2 for obesity, or ≥ 27 kg/m2 for overweight with comorbidity)
• Documentation of weight-related comorbidity if BMI 27-29.9 kg/m2
• For continuation: documentation of ≥ 5% weight loss after 12 weeks at therapeutic dose

Approval and renewal

• Renewal: At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation.
• Renewal: At least 12 weeks on therapy before the first renewal.

Not covered when

• Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended

Policy note: Available as subcutaneous injection solution (vial) and Kwikpen formulations. Indicated for adults only (age ≥ 18) for weight loss. The Asian BMI threshold of ≥ 23 kg/m2 is noted in the clinical rationale for South Asian, Southeast Asian, and East Asian adults. Efficacy should be assessed after 12 weeks at a therapeutic dose; continuation recommended only for patients achieving ≥ 5% weight loss.

Policy effective May 18, 2026 · verified June 5, 2026 · source: Capital BlueCross Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Diagnosis of moderate to severe OSA (AHI or REI ≥ 15 events/hour, or equivalent RDI)
• OSA diagnostic test result: polysomnography (PSG) preferred, or home sleep apnea test (HSAT) with technically adequate device
• BMI documentation ≥ 30 kg/m2 (obesity)
• If HSAT result is negative, inconclusive, or technically inadequate: PSG results required
• Documentation confirming OSA is not predominantly central or mixed (< 50% central or mixed apneas/hypopneas)

Not covered when

• Craniofacial abnormalities affecting respiration
• Predominantly central or mixed sleep apnea (≥ 50% central or mixed apneas/hypopneas)
• Cheyne-Stokes respiration
• Obesity hypoventilation syndrome
• Evidence of daytime hypercapnia
• Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended

Policy note: FDA-approved for moderate to severe OSA in adults with obesity. The SURMOUNT-OSA program (two phase 3 trials) enrolled participants with mean AHIs of ~50 events/hour and mean BMIs ~39 kg/m2. Trial 1 enrolled participants NOT receiving PAP therapy; Trial 2 enrolled participants already on PAP therapy — indicating PAP trial is NOT required for eligibility. OSA severity grading uses AHI (PSG-derived, preferred), REI (HSAT-based surrogate), or RDI (broader physiologic assessment). The 'moderate to severe' OSA threshold per AASM standards is AHI/REI ≥ 15 events/hour; the document does not explicitly state a numeric threshold in the criteria section but the FDA indication and SURMOUNT-OSA trial context supports ≥ 15 as the qualifying threshold. Hypopnea scoring per AASM recommended rule: ≥ 30% airflow reduction ≥ 10 seconds with ≥ 3% O2 desaturation and/or arousal.

Policy effective May 18, 2026 · verified June 5, 2026 · source: Capital BlueCross Employer / Commercial Insurance prior authorization policy · View policy document (PDF)